Key result
PBMC reprogramming generates 3 validated iPSC lines to model ICI-associated myocarditis.
Why the study?
Immune checkpoint inhibitor-associated myocarditis has up to 40% mortality, but the underlying mechanisms remain elusive partly due to a lack of appropriate human disease models.
The establishment of these patient-derived iPSC lines provides a genetically faithful human model for investigating the mechanisms of immune checkpoint inhibitor-associated myocarditis.
Patient-derived iPSC lines may enable mechanistic studies of ICI-myocarditis; leaves open any clinical translation.
Immune checkpoint inhibitor-associated myocarditis (ICIM) is an uncommon but potentially fatal inflammatory heart disease triggered by cancer immunotherapy, with up to 40% mortality. The underlying mechanisms are still elusive, partly due to the lack of appropriate human disease models. Here, we report the generation of three induced pluripotent stem cell (iPSC) lines derived from an ICIM patient, an ICI-treated patient without myocarditis, and a healthy donor. These lines exhibit typical pluripotent stem cell morphology, express pluripotency markers, maintain normal karyotypes, and differentiate into derivatives of the three germ layers, providing a valuable platform for mechanistic studies and therapeutic discovery.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Immune checkpoint inhibitor-associated myocarditis (n=3). iPSC generation vs. Healthy donor and ICI-treated patient without myocarditis was evaluated on Successful generation and characterization of iPSC lines. Three induced pluripotent stem cell lines were successfully generated from a patient with immune checkpoint inhibitor-associated myocarditis, an ICI-treated control, and a healthy donor, demonstrating normal karyotypes and pluripotency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: